U.S. markets closed

MorphoSys AG (MOR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
5.45+0.11 (+2.06%)
At close: 03:59PM EDT
5.45 0.00 (0.00%)
After hours: 07:22PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Head and Shoulders Bottom

Head and Shoulders Bottom

Previous Close5.34
Bid2.67 x 1100
Ask5.49 x 800
Day's Range5.38 - 5.49
52 Week Range4.35 - 22.18
Avg. Volume51,890
Market Cap744.443M
Beta (5Y Monthly)0.88
PE Ratio (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for MOR

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • MorphoSys AG
    Daily – Vickers Top Buyers & Sellers for 05/03/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    26 days agoArgus Research
View more
  • Motley Fool

    MorphoSys AG (MOR) Q1 2022 Earnings Call Transcript

    My name is Julia Neugebauer, senior director investor relations at MorphoSys, and it is my pleasure to welcome you to our first quarter 2022 financial results conference call. Joining me on the call today are Jean-Paul Kress, chief executive officer; Sung Lee, chief financial officer; Malte Peters, chief research and development officer; and Joe Horvat, U.S. general manager.

  • Zacks

    Wall Street Analysts Believe MorphoSys AG Unsponsored ADR (MOR) Could Rally 213%: Here's is How to Trade

    The mean of analysts' price targets for MorphoSys AG Unsponsored ADR (MOR) points to a 213.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

  • Benzinga

    MorphoSys-Incyte Partnered Minjuvi Temporarily Approved In Switzerland

    The Swiss agency for therapeutic products has granted temporary approval for MorphoSys AG (NASDAQ: MOR) and Incyte Corp's (NASDAQ: INCY) Minjuvi (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The approval comes for Minjuvi combined with lenalidomide, followed by Minjuvi monotherapy for adult patients, after at least one prior line of systemic therapy, who are not eligible for autologous stem cell transplant (ASCT). The approval is based on the results from the L-